Can we still innovate in Drug Design? Do we have to follow Lipinski's rules of five? Are metals really toxic? This talk will try to shake up conventional thinking and disclose a new class of metallic drugs.Surprisingly, for centuries, most anticancer drugs have been based on purely organic scaffolds. Bioorganometallic chemistry was first defined in the 1980s. During its infancy, the field was clearly overshadowed by the supremacy of research on organometallic catalysts, since it was assumed that organometallic complexes were incompatible with oxygen and water and, thus, unsuitable for use in biological systems. Despite the enormous potential of organometallic drugs, this new field remains underestimated and understudied. Our group has recently discovered, synthesised and patented Cymanquine, a novel organomanganese-containing compound which exhibits promising anticancer and parasitic activities. Through this talk, we will disclose a new approach to drug design that relies on combining electrochemistry with organometallic and medicinal chemistry.